Premium
Lower plasma pantoprazole level predicts Helicobacter pylori treatment failure in patients with type 2 diabetes mellitus
Author(s) -
Sapmaz Ferdane,
Kalkan Ismail H,
Suslu Incilay,
Demirci Hüseyin,
Atasoy Pinar,
Guliter Sefa
Publication year - 2015
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/1751-2980.12272
Subject(s) - medicine , pantoprazole , helicobacter pylori , gastroenterology , diabetes mellitus , type 2 diabetes mellitus , type 2 diabetes , endocrinology , omeprazole
Objective We aimed to compare the plasma pantoprazole level ( PPL) between patients with type 2 diabetes mellitus and non‐diabetic patients during Helicobacter pylori ( H. pylori ) eradication treatment and to explore the role of PPL in predicting the treatment success rates. Methods This study included 40 diabetic and 40 non‐diabetic treatment‐naive H. pylori ‐infected patients. Bismuth‐based standard quadruple treatment for H. pylori eradication was used for 14 days in both groups. PPL was measured using the square‐wave voltammetry method. Results H. pylori eradication rate (60.0% vs 87.5%, P = 0.005) and PPL (0.25 ± 0.03 μg/mL vs 0.34 ± 0.03 μg/mL, P < 0.001) was significantly lower in the diabetic group compared with the controls. Patients with treatment failure had lower PPL than those with successful treatment ( P < 0.001). The receiver operating characteristics curve demonstrated that PPL had a significant predictive value for the outcome of H. pylori eradication. Conclusion Type 2 diabetic patients had lower PPL than the non‐diabetic controls, which led to their lower H . pylori eradication rates.